InVivo Therapeutics Holdings Corporation
InVivo Therapeutics Holdings Corporation (NVIVQ) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
nvivq · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
InVivo Therapeutics Holdings CorporationYou NVIVQ | $1M | N/A | — | -$6.62 |
 Digipath, Inc. DIGP | $1M | N/A | — | -$0.02 |
 Evolva Holding S.A. ELVAY | $1M | 1302.74x | — | $0.14 |
 Entourage Health Corp. ETRGF | $1M | N/A | — | -$0.15 |
 HCYTD HCYTD | — | N/A | — | — |
 Novation Companies, Inc. NOVC | $1M | N/A | — | -$0.08 |
 Nutroganics, Inc. NUTTQ | $1M | N/A | — | -$0.16 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for InVivo Therapeutics Holdings Corporation (NVIVQ) measures how much investors pay for each dollar of the company's trailing earnings. NVIVQ's current PE ratio of N/A is calculated by dividing its stock price of $0.37 by its TTM earnings per share of -$6.62.
Frequently asked questions
NVIVQ pe ratio · 6 questionsNVIVQ's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.37 and TTM EPS of -$6.62. Data sourced from Financial Modeling Prep via NVIVQ's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · InVivo Therapeutics Holdings Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09